Campath and Hyperthyroidism - a phase IV clinical study of FDA data

Summary:

Hyperthyroidism is reported as a side effect among people who take Campath (alemtuzumab), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Baclofen, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Hyperthyroidism when taking Campath. It is created by eHealthMe based on reports of 4,897 people who have side effects when taking Campath from the FDA, and is updated regularly.

What is Campath?

Campath has active ingredients of alemtuzumab. eHealthMe is studying from 4,909 Campath users. Check the latest studies of Campath.

What is Hyperthyroidism?

Hyperthyroidism (over activity of the thyroid gland) is found to be associated with 997 drugs and 1,435 conditions by eHealthMe. Check the latest studies of Hyperthyroidism.

On Apr, 16, 2026

4,897 people reported to have side effects when taking Campath.
Among them, 43 people (0.88%) have Hyperthyroidism.

Among these 43 people:

How long have people been on Campath when they have Hyperthyroidism? *

What is the gender of people who have Hyperthyroidism when taking Campath? *

female: 65.71 %
male: 34.29 %

What is the age of people who have Hyperthyroidism when taking Campath? *

What are other drugs people take besides Campath? *

What are other side effects people have besides Hyperthyroidism? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 16 people, 37.21%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 8 people, 18.60%
Thyroiditis (inflammation of thyroid gland): 6 people, 13.95%
Thyroid Cancer: 6 people, 13.95%
Inflammation: 4 people, 9.30%
Headache (pain in head): 4 people, 9.30%
Fever: 4 people, 9.30%
Rashes (redness): 4 people, 9.30%
Anti-Thyroid Antibody Positive: 3 people, 6.98%
Tremor (trembling or shaking movements in one or more parts of your body): 3 people, 6.98%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 17 people, 39.53%
Asthma: 7 people, 16.28%
Birth Control: 6 people, 13.95%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 5 people, 11.63%
Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 2 people, 4.65%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (long lasting infection of nerves outside brain and spinal cord): 2 people, 4.65%
Red Cell Aplasia (a type of anaemia affecting the precursors to red blood cells): 1 person, 2.33%
Pain: 1 person, 2.33%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 2.33%
Aplasia Pure Red Cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells): 1 person, 2.33%

* Approximation only. Some reports may have incomplete information.

Do you take Campath and have Hyperthyroidism?

- Check whether Hyperthyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Campath:

Campath (4,909 reports)

Hyperthyroidism treatments and more:

Hyperthyroidism (26,832 reports)

Browse all side effects of Campath:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperthyroidism:

Hyperthyroidism (997 drugs)

Browse all the conditions that are associated with Hyperthyroidism:

Hyperthyroidism (1,435 conditions)

Related publications that referenced our studies

Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .
Dulani S, Dulani R, Lele S, Diagavane S, Anjankar S, Jaiswal N, Subramaniam PS, Juneja R, "Chronic Subdural Haematoma in a Case of Hyperthyroidism Presenting with Papilledema", Chinese Medicine, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Campath) and Campath (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.